A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
for Chronic Inducible Urticaria
26 locations incl. Birmingham
Sponsor: Celldex Therapeutics
Sex: All·Age: 18+
Code: NCT07266402·Phase 3·Recruiting·Listed Dec 2025